Dehydrated Human Amniotic Membrane Inhibits Myofibroblast Contraction through the Regulation of the TGFβ‒SMAD Pathway...

Area of Science:

• Regenerative Medicine
• Wound Healing
• Tissue Engineering

Background:

• Excessive fibrosis, characterized by extracellular matrix accumulation, affects millions annually, impairing tissue function.
• The amniotic membrane shows potential for antifibrotic therapies.
• Investigating dehydrated human amnion/chorion membrane (dHACM) effects on fibroblast-driven fibrosis is crucial.

Purpose of the Study:

• To investigate the antifibrotic effects of dHACM on human dermal fibroblasts.
• To elucidate the impact of dHACM on transforming growth factor beta 1 (TGFβ1) signaling pathways.
• To assess dHACM's role in modulating fibroblast-mediated extracellular matrix production and cellular contraction.

Main Methods:

• Human dermal fibroblasts were stimulated with TGFβ1 to induce myofibroblast differentiation in vitro.
• dHACM was added to TGFβ1-stimulated fibroblasts to assess its impact on fibrotic gene expression.
• Cellular contraction was evaluated using an ex vivo collagen gel contraction model.

Main Results:

• dHACM inhibited TGFβ1-induced downstream signaling pathways.
• dHACM significantly reduced the expression of fibrotic and extracellular matrix genes.
• dHACM decreased alpha-smooth muscle actin expression and attenuated myofibroblast-mediated collagen gel contraction.

Conclusions:

• dHACM demonstrates potent antifibrotic properties by modulating fibroblast activity and TGFβ signaling.
• These findings support the potential therapeutic application of dHACM in managing fibrotic diseases.
• dHACM may serve as a valuable agent for regulating fibroblast behavior in scar reduction and tissue repair.